Adiponectin, lipids and atherosclerosis

Current Opinion in Lipidology

Volumn 28, Issue 4, 2017, Pages 347-354

  Katsiki, Niki ^a   Mantzoros, Christos ^b   Mikhailidis, Dimitri P ^c  

^a ARISTOTLE UNIVERSITY MEDICAL SCHOOL   (Greece)

^b HARVARD MEDICAL SCHOOL   (United States)

^c ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

Author keywords

adiponectin; atherosclerosis; coronary heart disease; lipids; noncardiac vascular diseases

Indexed keywords

ACETYLSALICYLIC ACID; ADIPONECTIN; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIDIABETIC AGENT; ANTIHYPERTENSIVE AGENT; ATORVASTATIN; CALCIUM CHANNEL BLOCKING AGENT; CHRS 131; DAPAGLIFLOZIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; EMPAGLIFLOZIN; EXENDIN 4; EZETIMIBE; GLIMEPIRIDE; LIPID; LIRAGLUTIDE; METFORMIN; NICOTINIC ACID; OMEGA 3 FATTY ACID; PIOGLITAZONE; PITAVASTATIN; PRAVASTATIN; SIMVASTATIN; SITAGLIPTIN; UNCLASSIFIED DRUG; VILDAGLIPTIN;

ABDOMINAL AORTIC ANEURYSM; ATHEROSCLEROSIS; BARIATRIC SURGERY; BRAIN ISCHEMIA; CARDIOEMBOLIC STROKE; CARDIOMETABOLIC RISK; CAROTID ARTERY DISEASE; CEREBROVASCULAR ACCIDENT; CHRONIC KIDNEY FAILURE; DYSLIPIDEMIA; HUMAN; HYPERURICEMIA; INFLAMMATION; INSULIN RESISTANCE; ISCHEMIC HEART DISEASE; KIDNEY ARTERY STENOSIS; LIFESTYLE MODIFICATION; META ANALYSIS (TOPIC); METABOLIC SYNDROME X; NON INSULIN DEPENDENT DIABETES MELLITUS; NONALCOHOLIC FATTY LIVER; OBESITY; PERIPHERAL OCCLUSIVE ARTERY DISEASE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; COMPLICATION; LIFESTYLE; LIPID METABOLISM; METABOLISM;

ADIPONECTIN; ATHEROSCLEROSIS; BARIATRIC SURGERY; HUMANS; LIFE STYLE; LIPID METABOLISM; OBESITY;

EID: 85026438667     PISSN: 09579672     EISSN: 14736535     Source Type: Journal    
DOI: 10.1097/MOL.0000000000000431     Document Type: Review

References (142)

1. Parker-Duffen JL, Walsh K. Cardiometabolic effects of adiponectin. Best Pract Res Clin Endocrinol Metab 2014; 28:81-91.
2. Balsan GA, Vieira JL, Oliveira AM, Portal VL. Relationship between adiponectin, obesity and insulin resistance. Rev Assoc Med Bras (1992) 2015; 61:72-80.
3. Shen L, Evans IM, Souza D, et al. Adiponectin: an endothelium-derived vasoprotective factor? Curr Vasc Pharmacol 2016; 14:168-174.
4. Gairolla J, Kler R, Modi M, Khurana D. Leptin and adiponectin: pathophysiological role and possible therapeutic target of inflammation in ischemic stroke. Rev Neurosci 2017; 28:295-306.
5. Ruscica M, Baragetti A, Catapano AL, Norata GD. Translating the biology of adipokines in atherosclerosis and cardiovascular diseases: gaps and open questions. Nutr Metab Cardiovasc Dis 2016. [Epub ahead of print]
6. Ruan H, Dong LQ. Adiponectin signaling and function in insulin target tissues. J Mol Cell Biol 2016; 8:101-109.
7. Andrade-Oliveira V, Câmara NO, Moraes-Vieira PM. Adipokines as drug targets in diabetes and underlying disturbances. J Diabetes Res 2015; 2015:681612.
8. Ebrahimi-Mamaeghani M, Mohammadi S, Arefhosseini SR, et al. Adiponectin as a potential biomarker of vascular disease. Vasc Health Risk Manag 2015; 11:55-70.
9. Ibrahim NE, Januzzi JL Jr, Magaret CA, et al. A clinical and biomarker scoring system to predict the presence of obstructive coronary artery disease. J Am Coll Cardiol 2017; 69:1147-1156.
10. Hossain MM, Mukheem A, Kamarul T. The prevention and treatment of hypoadiponectinemia-associated human diseases by up-regulation of plasma adiponectin. Life Sci 2015; 135:55-67.
11. Kizer JR. Adiponectin, cardiovascular disease, and mortality: parsing the dual prognostic implications of a complex adipokine. Metabolism 2014; 63:1079-1083.
12. Christou GA, Kiortsis DN. Adiponectin and lipoprotein metabolism. Obes Rev 2013; 14:939-949.
13. Krautbauer S, Neumeier M, Eisinger K, et al. LDL but not HDL increases adiponectin release of primary human adipocytes. Exp Mol Pathol 2013; 95:325-329.
14. Dastani Z, Hivert MF, Timpson N, et al. Novel loci for adiponectin levels and their influence on type 2 diabetes and metabolic traits: a multiethnic metaanalysis of 45,891 individuals. PLoS Genet 2012; 8:e1002607.
15. Zhao T, Zhao J. Genetic effects of adiponectin on blood lipids and blood pressure. Clin Endocrinol (Oxf) 2011; 74:214-222.
16. Matsuzawa Y. Adiponectin: identification, physiology and clinical relevance in metabolic and vascular disease. Atheroscler Suppl 2005; 6:7-14.
17. Shirakawa T, Nakajima K, Yatsuzuka S, et al. The role of circulating lipoprotein lipase and adiponectin on the particle size of remnant lipoproteins in patients with diabetes mellitus and metabolic syndrome. Clin Chim Acta 2015; 440:123-132.
18. Gibas-Dorna M, Piątek J, Kupsz J, et al. Relationship between adipokines and lipid profile in postmenopausal women with different apolipoprotein E genotypes. Women Health 2016; 1-14. [Epub ahead of print]
19. Maghsoudi Z, Kelishadi R, Hosseinzadeh-Attar MJ. The comparison of chemerin, adiponectin and lipid profile indices in obese and nonobese adolescents. Diabetes Metab Syndr 2016; 10 (2 Suppl 1): S43-S46.
20. Gradinaru D, Margina D, Borsa C, et al. Adiponectin: possible link between metabolic stress and oxidative stress in the elderly. Aging Clin Exp Res 2016; 1-14. [Epub ahead of print]
21. Eslamian M, Mohammadinejad P, Aryan Z, et al. Positive correlation of serum adiponectin with lipid profile in patients with type 2 diabetes mellitus is affected by metabolic syndrome status. Arch Iran Med 2016; 19:269-274.
22. Durrani S, Shah J, Khan MA, Jan MR. Relationship of adiponectin level with lipid profile in type-2 diabetic men with coronary heart disease. J Ayub Med Coll Abbottabad 2015; 27:32-35.
23. Mikhailidis DP, Elisaf M, Rizzo M, et al. European panel on low density lipoprotein (LDL) subclasses': a statement on the pathophysiology, atherogenicity and clinical significance of LDL subclasses: executive summary. Curr Vasc Pharmacol 2011; 9:531-532.
24. Mikhailidis DP, Elisaf M, Rizzo M, et al. European panel on low density lipoprotein (LDL) subclasses': a statement on the pathophysiology, atherogenicity and clinical significance of LDL subclasses. Curr Vasc Pharmacol 2011; 9:533-571.
25. Satoh N, Wada H, Ono K, et al. Small dense LDL-cholesterol relative to LDLcholesterol is a strong independent determinant of hypoadiponectinemia in metabolic syndrome. Circ J 2008; 72:932-939.
26. Marso SP, Mehta SK, Frutkin A, et al. Low adiponectin levels are associated with atherogenic dyslipidemia and lipid-rich plaque in nondiabetic coronary arteries. Diabetes Care 2008; 31:989-994.
27. Hulthe J, Hultén LM, Fagerberg B. Low adipocyte-derived plasma protein adiponectin concentrations are associated with the metabolic syndrome and small dense low-density lipoprotein particles: atherosclerosis and insulin resistance study. Metabolism 2003; 52:1612-1614.
28. Tune JD, Goodwill AG, Sassoon DJ, Mather KJ. Cardiovascular consequences of metabolic syndrome. Transl Res 2017; 183:57-70.
29. Katsiki N, Athyros VG, Karagiannis A, Mikhailidis DP. High-density lipoprotein, vascular risk, cancer and infection: a case of quantity and quality? Curr Med Chem 2014; 21:2917-2926.
30. Goldberg RB, Temprosa M, Mele L, et al., Diabetes Prevention Program Research Group. Change in adiponectin explains most of the change in HDL particles induced by lifestyle intervention but not metformin treatment in the Diabetes Prevention Program. Metabolism 2016; 65:764-775.
31. Kolovou GD, Mikhailidis DP, Kovar J, et al. Assessment and clinical relevance of nonfasting and postprandial triglycerides: an expert panel statement. Curr Vasc Pharmacol 2011; 9:258-270.
32. Perez-Martinez P, Alcala-Diaz JF, Kabagambe EK, et al. Assessment of postprandial triglycerides in clinical practice: validation in a general population and coronary heart disease patients. J Clin Lipidol 2016; 10:1163-1171.
33. Kennedy A, Spiers JP, Crowley V, et al. Postprandial adiponectin and gelatinase response to a high-fat versus an isoenergetic low-fat meal in lean, healthy men. Nutrition 2015; 31:863-870.
34. Phillips LK, Peake JM, Zhang X, et al. Postprandial total and HMW adiponectin following a high-fat meal in lean, obese and diabetic men. Eur J Clin Nutr 2013; 67:377-384.
35. Nagata T, Sugiyama D, Kise T, et al. Fasting remnant lipoproteins can predict postprandial hyperlipidemia. Lipids Health Dis 2012; 11:146.
36. Katsiki N, Mantzoros CS. Statins in relation to adiponectin: a significant association with clinical implications. Atherosclerosis 2016; 253: 270-272.
37. Chruściel P, Sahebkar A, Rembek-Wieliczko M, et al., Lipid and Blood Pressure Meta-analysis Collaboration (LBPMC) Group. Impact of statin therapy on plasma adiponectin concentrations: A systematic review and meta-analysis of 43 randomized controlled trial arms. Atherosclerosis 2016; 253:194-208.
38. Arnaboldi L, Corsini A. Could changes in adiponectin drive the effect of statins on the risk of new-onset diabetes? The case of pitavastatin. Atheroscler Suppl 2015; 16:1-27.
39. Chan DC, Pang J, Watts GF. Pathogenesis and management of the diabetogenic effect of statins: a role for adiponectin and coenzyme Q10? Curr Atheroscler Rep 2015; 17:472.
40. Katsiki N, Rizzo M, Mikhailidis DP, Mantzoros CS. New-onset diabetes and statins: throw the bath water out, but, please, keep the baby! Metabolism 2015; 64:471-475.
41. Brault M, Ray J, Gomez YH, et al. Statin treatment and new-onset diabetes: a review of proposed mechanisms. Metabolism 2014; 63:735-745.
42. Krysiak R, Žmuda W, Marek B, OkopieńB. Age may determine the effect of hypolipidemic agents on plasma adipokine levels in patients with elevated low-density lipoprotein cholesterol levels. Endokrynol Pol 2016; 67:271-276.
43. Koh KK, Oh PC, Sakuma I, Kim EY, et al. Vascular and metabolic effects of ezetimibe combined with simvastatin in patients with hypercholesterolemia. Int J Cardiol 2015; 199:126-131.
44. Takase H, Dohi Y, Okado T, et al. Effects of ezetimibe on visceral fat in the metabolic syndrome: a randomised controlled study. Eur J Clin Invest 2012; 42:1287-1294.
45. Dolezelova E, Stein E, Derosa G, et al. Effect of ezetimibe on plasma adipokines: a systematic review and meta-analysis. Br J Clin Pharmacol 2017. [Epub ahead of print]
46. Sahebkar A, Watts GF. Fibrate therapy and circulating adiponectin concentrations: a systematic review and meta-analysis of randomized placebocontrolled trials. Atherosclerosis 2013; 230:110-120.
47. Liu D, Wang X, Kong L, Chen Z. Nicotinic acid regulates glucose and lipid metabolism through lipid independent pathways. Curr Pharm Biotechnol 2015; 16:3-10.
48. HuM, Yang YL, Masuda D, et al. Effect of extended-release niacin/laropiprant combination on plasma adiponectin and insulin resistance in Chinese patients with dyslipidaemia. Dis Markers 2015; 2015:154014.
49. Barbosa MM,Melo AL, Damasceno NR. The benefits of v-3 supplementation depend on adiponectin basal level and adiponectin increase after the supplementation: a randomized clinical trial. Nutrition 2017; 34:7-13.
50. Alsaleh A, Crepostnaia D, Maniou Z, et al., MARINA study team. Adiponectin gene variant interacts with fish oil supplementation to influence serum adiponectin in older individuals. J Nutr 2013; 143:1021-1027.
51. Lopez-Jaramillo P. The role of adiponectin in cardiometabolic diseases: effects of nutritional interventions. J Nutr 2016; 146:422S-426S.
52. Zhang H, Mo X, Hao Y, et al. Adiponectin levels and risk of coronary heart disease: a meta-analysis of prospective studies. Am J Med Sci 2013; 345:455-461.
53. Zhang BC, Liu WJ, Che WL, Xu YW. Serum total adiponectin level and risk of cardiovascular disease in Han Chinese populations: a meta-analysis of 17 case-control studies. Clin Endocrinol (Oxf) 2012; 77:370-378.
54. Hao G, Li W, Guo R, et al. Serum total adiponectin level and the risk of cardiovascular disease in general population: a meta-analysis of 17 prospective studies. Atherosclerosis 2013; 228:29-35.
55. Sook Lee E, Park SS, Kim E, et al. Association between adiponectin levels and coronary heart disease and mortality: a systematic review and metaanalysis. Int J Epidemiol 2013; 42:1029-1039.
56. Borges MC, Lawlor DA, de Oliveira C, et al. Role of adiponectin in coronary heart disease risk: a Mendelian randomization study. Circ Res 2016; 119:491-499.
57. Seven E, Husemoen LL, Sehested TS, et al. Adipocytokines, C-reactive protein, and cardiovascular disease: a population-based prospective study. PLoS One 2015; 10:e0128987.
58. Mackey RH, McTigue KM, Chang YF, et al. Lipoprotein particles and size, total and high molecularweight adiponectin, and leptin in relation to incident coronary heart disease among severely obese postmenopausal women: The Women's Health Initiative Observational Study. BBA Clin 2015; 3:243-250.
59. Jin Z, Pu L, Sun L, et al. Identification of susceptibility variants in ADIPOR1 gene associated with type 2 diabetes, coronary artery disease and the comorbidity of type 2 diabetes and coronary artery disease. PLoS One 2014; 9:e100339.
60. Cheung CY, Hui EY, Cheung BM, et al. Adiponectin gene variants and the risk of coronary heart disease: a 16-year longitudinal study. Eur J Endocrinol 2014; 171:107-115.
61. Kawagoe J, Ishikawa T, Iwakiri H, et al. Association between adiponectin production in coronary circulation and future cardiovascular events in patients with coronary artery disease. Int Heart J 2014; 55:239-243.
62. Zhang HL, Jin X. Relationship between serum adiponectin and osteoprotegerin levels and coronary heart disease severity. Genet Mol Res 2015; 14:11023-11029.
63. Lindberg S, Jensen JS, Hoffmann S, et al. Interplay between adiponectin and pro-atrial natriuretic peptide and prognosis in patients with ST-segment elevation myocardial infarction. Am J Cardiol 2015; 116:1340-1345.
64. Katsiki N, Athyros VG, Mikhailidis DP. Abnormal peri-organ or intra-organ fat (APIFat) deposition: an underestimated predictor of vascular risk? Curr Vasc Pharmacol 2016; 14:432-441.
65. Katsiki N, Mikhailidis DP, Wierzbicki AS. Epicardial fat and vascular risk: a narrative review. Curr Opin Cardiol 2013; 28:458-463.
66. Katsiki N, Mikhailidis DP. Epicardial fat: a novel marker of subclinical atherosclerosis in clinical practice? Anatol J Cardiol 2017; 17:64-65.
67. Salazar J, Luzardo E, Mejías JC, et al. Epicardial fat: physiological, pathological, and therapeutic implications. Cardiol Res Pract 2016; 2016:1291537.
68. Fernández-Trasancos Á, Guerola-Segura R, Paradela-Dobarro B, et al. Glucose and inflammatory cells decrease adiponectin in epicardial adipose tissue cells: paracrine consequences on vascular endothelium. J Cell Physiol 2016; 231:1015-1023.
69. Tishinsky JM, Robinson LE, Dyck DJ. Insulin-sensitizing properties of adiponectin. Biochimie 2012; 94:2131-2136.
70. Yuan HP, Sun L, Li XH, et al. Association of adiponectin polymorphism with metabolic syndrome risk and adiponectin level with stroke risk: a metaanalysis. Sci Rep 2016; 6:31945.
71. Kanhai DA, Kranendonk ME, Uiterwaal CS, et al. Adiponectin and incident coronary heart disease and stroke. A systematic review and meta-analysis of prospective studies. Obes Rev 2013; 14:555-567.
72. Shen D, Xing S, Chen C. Adiponectin gene polymorphisms contributes to ischemic stroke risk: a meta-analysis. J Renin Angiotensin Aldosterone Syst 2015; 16:178-184.
73. Kuwashiro T, Ago T, Kamouchi M, et al. Significance of plasma adiponectin for diagnosis, neurological severity and functional outcome in ischemic stroke: Research for Biomarkers in Ischemic Stroke (REBIOS). Metabolism 2014; 63:1093-1103.
74. Bienek R, Marek B, Kajdaniuk D, et al. Adiponectin, leptin, resistin and insulin blood concentrations in patients with ischaemic cerebral stroke. Endokrynol Pol 2012; 63:338-345.
75. Marousi SG, Theodorou GL, Karakantza M, et al. Acute poststroke adiponectin in relation to stroke severity, progression and 6 month functional outcome. Neurol Res 2010; 32:841-844.
76. Sener U, Uludag IF, Kose S, et al. Is adiponectin a risk factor for transient ischaemic attacks? Endokrynol Pol 2015; 66:214-218.
77. Kishida K, Funahashi T, Shimomura I. Adiponectin as a routine clinical biomarker. Best Pract Res Clin Endocrinol Metab 2014; 28:119-130.
78. Sharma G, Kulkarni R, Shah SK, et al. Local perivascular adiponectin associates with lower extremity vascular operative wound complications. Surgery 2016; 160:204-210.
79. Persson J, Strawbridge RJ, McLeod O, et al., IMPROVE Study Group. Sexspecific effects of adiponectin on carotid intima-media thickness and incident cardiovascular disease. J Am Heart Assoc 2015; 4:e001853.
80. Fan LH, He Y, Xu W, et al. Adiponectin may be a biomarker of early atherosclerosis of smokers and decreased by nicotine through KATP channel in adipocytes. Nutrition 2015; 31 (7-8):955-958.
81. Sharma G, Tao M, Ding K, et al. Perivascular adipose adiponectin correlates with symptom status of patients undergoing carotid endarterectomy. Stroke 2015; 46:1696-1699.
82. Cai X, Li X, Li L, et al. Adiponectin reduces carotid atherosclerotic plaque formation in ApoE-/- mice: roles of oxidative and nitrosative stress and inducible nitric oxide synthase. Mol Med Rep 2015; 11:1715-1721.
83. Hui E, Xu A, Chow WS, et al. Hypoadiponectinemia as an independent predictor for the progression of carotid atherosclerosis: a 5-year prospective study. Metab Syndr Relat Disord 2014; 12:517-522.
84. Nowakowska-Fortuna E, Saeed A, Guron G, et al. Brain natriuretic peptides in atherosclerotic renal artery stenosis and effects of renal angioplasty. Kidney Blood Press Res 2013; 37:657-666.
85. Wågsäter D, Vorkapic E, van Stijn CM, et al. Elevated adiponectin levels suppress perivascular and aortic inflammation and prevent AngII-induced advanced abdominal aortic aneurysms. Sci Rep 2016; 6:31414.
86. Yoshida S, Fuster JJ, Walsh K. Adiponectin attenuates abdominal aortic aneurysm formation in hyperlipidemic mice. Atherosclerosis 2014; 235:339-346.
87. Golledge J, Clancy P, Jamrozik K, Norman PE. Obesity, adipokines, and abdominal aortic aneurysm: health in men study. Circulation 2007; 116:2275-2279.
88. Heidari M, Nasri P, Nasri H. Adiponectin and chronic kidney disease: a review on recent findings. J Nephropharmacol 2015; 4:63-68.
89. Jia T, Carrero JJ, Lindholm B, Stenvinkel P. The complex role of adiponectin in chronic kidney disease. Biochimie 2012; 94:2150-2156.
90. Sweiss N, Sharma K. Adiponectin effects on the kidney. Best Pract Res Clin Endocrinol Metab 2014; 28:71-79.
91. Stenvinkel P. Adiponectin in chronic kidney disease: a complex and context sensitive clinical situation. J Ren Nutr 2011; 21:82-86.
92. Zhou Y, Zhang J, Zhang W, Ni Z. Association of adiponectin with peripheral arterial disease and mortality in nondiabetic hemodialysis patients: long-term follow-up data of 7 years. J Res Med Sci 2016; 21:50.
93. Katsiki N, Athyros VG, Karagiannis A, et al. Should we expand the concept of coronary heart disease equivalents? Curr Opin Cardiol 2014; 29:389-395.
94. Katsiki N, Athyros VG, Karagiannis A, Mikhailidis DP. Metabolic syndrome and noncardiac vascular diseases: an update from human studies. Curr Pharm Des 2014; 20:4944-4952.
95. Srikanthan K, Feyh A, Visweshwar H, et al. Systematic review of metabolic syndrome biomarkers: a panel for early detection, management, and risk stratification in the west virginian population. Int J Med Sci 2016; 13:25-38.
96. Cho SA, Joo HJ, Cho JY, et al. Visceral fat area and serum adiponectin level predict the development of metabolic syndrome in a community-based asymptomatic population. PLoS One 2017; 12:e0169289.
97. Yoon CY, Kim YL, Han SH, et al. Hypoadiponectinemia and the presence of metabolic syndrome in patients with chronic kidney disease: results from the KNOW-CKD study. Diabetol Metab Syndr 2016; 8:75.
98. Song YM, Lee K, Sung J. Adiponectin levels and longitudinal changes in metabolic syndrome: the healthy twin study. Metab Syndr Relat Disord 2015; 13:312-318.
99. Zhou JM, Zhang M, Wang S, et al. Association of the ADIPOQ Rs2241766 and Rs266729 polymorphisms with metabolic syndrome in the Chinese population: a meta-analysis. Biomed Environ Sci 2016; 29:505-515.
100. Katsiki N, Mikhailidis DP, Mantzoros CS. Nonalcoholic fatty liver disease and dyslipidemia: an update. Metabolism 2016; 65:1109-1123.
101. Polyzos SA, Kountouras J, Mantzoros CS. Adipokines in nonalcoholic fatty liver disease. Metabolism 2016; 65:1062-1079.
102. Petta S, Gastaldelli A, Rebelos E, et al. Pathophysiology of nonalcoholic fatty liver disease. Int J Mol Sci 2016; 17.
103. Polyzos SA, Mantzoros CS. Adiponectin as a target for the treatment of nonalcoholic steatohepatitis with thiazolidinediones: a systematic review. Metabolism 2016; 65:1297-1306.
104. Zhang W, Zhu LQ, Huo XL, et al. Association between adiponectin gene T45G polymorphism and nonalcoholic fatty liver disease risk: a meta-analysis. Genet Mol Res 2016; 15:. doi: 10.4238/gmr.15017190.
105. Wang BF, Wang Y, Ao R, et al. AdipoQ T45 G and G276 T polymorphisms and susceptibility to nonalcoholic fatty liver disease among Asian populations: ameta-analysis and meta-regression. J Clin Lab Anal 2016; 30:47-57.
106. Blüher M, Mantzoros CS. From leptin to other adipokines in health and disease: facts and expectations at the beginning of the 21st century. Metabolism 2015; 64:131-145.
107. Liu C, Feng X, Li Q, et al. Adiponectin, TNF-a and inflammatory cytokines and risk of type 2 diabetes: a systematic review and meta-analysis. Cytokine 2016; 86:100-109.
108. Ghoshal K, Bhattacharyya M. Adiponectin: probe of the molecular paradigm associating diabetes and obesity. World J Diab 2015; 6:151-166.
109. Fan Y, Wang K, Xu S, et al. Association between ADIPOQ +45T>G polymorphism and type 2 diabetes: a systematic review and meta-analysis. Int J Mol Sci 2014; 16:704-723.
110. Rodríguez AJ, Nunes Vdos S, Mastronardi CA, et al. Association between circulating adipocytokine concentrations and microvascular complications in patients with type 2 diabetes mellitus: a systematic review and meta-analysis of controlled cross-sectional studies. J Diab Compl 2016; 30:357-367.
111. Bergmark BA, Cannon CP, White WB, et al. Baseline adiponectin concentration and clinical outcomes among patients with diabetes and recent acute coronary syndrome in the EXAMINE trial. Diabetes Obes Metab 2017. [Epub ahead of print]
112. Katsiki N, Mikhailidis DP. Hyperuricaemia in cardiovascular diseases: a passive or an active player? Med Princ Pract 2015; 24:269-270.
113. Nishizawa T, Taniura T, Nomura S. Effects of febuxostat on platelet-derived microparticles and adiponectin in patients with hyperuricemia. Blood Coagul Fibrinolysis 2015; 26:887-892.
114. Borel AL, Nazare JA, Baillot A, et al. Cardiometabolic risk improvement in response to a 3-yr lifestyle modification program in men: contribution of improved cardiorespiratory fitness vs weight loss. Am J Physiol Endocrinol Metab 2017; 312:E273-E281.
115. Martínez-González MÁ, Ruiz-Canela M, Hruby A, et al. Intervention trials with the Mediterranean diet in cardiovascular prevention: understanding potential mechanisms through metabolomic profiling. J Nutr 2016. [Epub ahead of print]
116. Lombardi G, Sanchis-Gomar F, Perego S, et al. Implications of exercise-induced adipo-myokines in bone metabolism. Endocrine 2016; 54:284-305.
117. Coles CA. Adipokines in healthy skeletal muscle and metabolic disease. Adv Exp Med Biol 2016; 900:133-160.
118. Yu N, Ruan Y, Gao X, Sun J. Systematic review and meta-analysis of randomized, controlled trials on the effect of exercise on serum leptin and adiponectin in overweight and obese individuals. Horm Metab Res 2017; 49:164-173.
119. Biagioni MF, Mendes AL, Nogueira CR, et al. Bariatric Roux-En-Y gastric bypass surgery: adipocyte proteins involved in increased bone remodeling in humans. Obes Surg 2017. [Epub ahead of print]
120. Schmatz R, Bitencourt MR, Patias LD, et al. Evaluation of the biochemical, inflammatory and oxidative profile of obese patients given clinical treatment and bariatric surgery. Clin Chim Acta 2017; 465:72-79.
121. Hirotsu C, Tufik S, Andersen ML. Interactions between sleep, stress, and metabolism: From physiological to pathological conditions. Sleep Sci 2015; 8:143-152.
122. Simpson NS, Banks S, Arroyo S, Dinges DF. Effects of sleep restriction on adiponectin levels in healthy men and women. Physiol Behav 2010; 101:693-698.
123. Taveras EM, Rifas-Shiman SL, Rich-Edwards JW, et al. Association of maternal short sleep duration with adiposity and cardiometabolic status at 3 years postpartum. Obesity (Silver Spring) 2011; 19:171-178.
124. Shea SA, Hilton MF, Orlova C, et al. Independent circadian and sleep/wake regulation of adipokines and glucose in humans. J Clin Endocrinol Metab 2005; 90:2537-2544.
125. Crispim CA, Padilha HG, Zimberg IZ, et al. Adipokine levels are altered by shiftwork: a preliminary study. Chronobiol Int 2012; 29:587-594.
126. Lim S, Quon MJ, Koh KK. Modulation of adiponectin as a potential therapeutic strategy. Atherosclerosis 2014; 233:721-728.
127. Katsiki N, Mikhailidis DP, Gotzamani-Psarrakou A, et al. Effect of various treatments on leptin, adiponectin, ghrelin and neuropeptide Y in patients with type 2 diabetes mellitus. Expert Opin Ther Targets 2011; 15:401-420.
128. Rojas E, Rodríguez-Molina D, Bolli P, et al. The role of adiponectin in endothelial dysfunction and hypertension. Curr Hypertens Rep 2014; 16:463.
129. Tsuburaya R, Takahashi J, Nakamura A, et al., NOVEL Investigators. Beneficial effects of long-acting nifedipine on coronary vasomotion abnormalities after drug-eluting stent implantation: The NOVEL study. Eur Heart J 2016; 37:2713-2721.
130. Derosa G, Querci F, Franzetti I, et al. Comparison of the effects of barnidipine+losartan compared with telmisartan+hydrochlorothiazide on several parameters of insulin sensitivity in patients with hypertension and type 2 diabetes mellitus. Hypertens Res 2015; 38:690-694.
131. Fisman EZ, Tenenbaum A. Adiponectin: a manifold therapeutic target for metabolic syndrome, diabetes, and coronary disease? Cardiovasc Diabetol 2014; 13:103.
132. Su JR, Lu ZH, Su Y, et al. Relationship of serum adiponectin levels and metformin therapy in patients with type 2 diabetes. Horm Metab Res 2016; 48:92-98.
133. Liu X, Men P, Wang Y, et al. Impact of dipeptidyl peptidase-4 inhibitors on serum adiponectin: a meta-analysis. Lipids Health Dis 2016; 15:204.
134. Sahebkar A, Ponzo V, Bo S. Effect of dipeptidyl peptidase-4 inhibitors on plasma adiponectin: a systematic review and meta-analysis of randomized controlled trials. Curr Med Chem 2016; 23:1356-1369.
135. Dutour A, Abdesselam I, Ancel P, et al. Exenatide decreases liver fat content and epicardial adipose tissue in patients with obesity and type 2 diabetes: a prospective randomized clinical trial using magnetic resonance imaging and spectroscopy. Diabetes Obes Metab 2016; 18:882-891.
136. Han JH, Oh TJ, Lee G, et al. The beneficial effects of empagliflozin, an SGLT2 inhibitor, on atherosclerosis in ApoE (-/-) mice fed a western diet. Diabetologia 2017; 60:364-376.
137. Li D, Xu X, Zhang Y, et al. Liraglutide treatment causes upregulation of adiponectin and downregulation of resistin in Chinese type 2 diabetes. Diabetes Res Clin Pract 2015; 110:224-228.
138. Derosa G, Mugellini A, Pesce RM, et al. A study about the relevance of adding acetylsalicylic acid in primary prevention in subjects with type 2 diabetes mellitus: effects on some new emerging biomarkers of cardiovascular risk. Cardiovasc Diabetol 2015; 14:95.
139. Sun Y, Zang Z, Zhong L, et al. Identification of adiponectin receptor agonist utilizing a fluorescence polarization based high throughput assay. PLoS One 2013; 8:e63354.
140. Blackburn GL. From bench to bedside: novel mechanisms and therapeutic advances through the development of selective peroxisome proliferator-activated receptor gamma modulators. Am J Clin Nutr 2010; 91:251S-253S.
141. DePaoli AM, Higgins LS, Henry RR, et al., INT131-007 Study Group. Can a selective PPARg modulator improve glycemic control in patients with type 2 diabetes with fewer side effects compared with pioglitazone? Diab Care 2014; 37:1918-1923.
142. Higgins LS, Mantzoros CS. The development of INT131 as a selective PPARg modulator: approach to a safer insulin sensitizer. PPAR Res 2008; 2008:936906.